Continuing Anti-TNF Agents past 24 Weeks of Pregnancy Associated with Fewer IBD Relapses with No Increase in Adverse Fetal Outcomes

Ahmad Abu-Heija, MBBS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Benefits and Risks Associated with Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease,” by Meyer A, Neumann A, Drouin J, et al. Ann Intern Med [2022; 175(10) 1374-82].